Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing a downturn, with significant declines in several key companies, while the innovative drug ETF is seeing increased investment interest despite the market drop [1][3]. Group 1: Company Performance - Zai Lab reported a third-quarter product revenue net of $115.4 million, a year-on-year increase of 13%, with a net loss of $36 million, which is an improvement compared to the same period last year [3]. - BeiGene, known as the "king of innovative drugs," achieved a remarkable third-quarter revenue of 10.077 billion yuan, marking a year-on-year growth of 41.1%. The total revenue for the first three quarters reached 27.595 billion yuan, up 44.2% year-on-year, surpassing the total revenue of the previous year, with a net profit attributable to shareholders of 1.139 billion yuan [3]. Group 2: ETF Insights - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and offers better risk control by reducing the weight of less liquid stocks [4][5][6]. - As of the end of October, the top ten holdings in the index accounted for 71.51% of the total weight, indicating a strong representation of leading innovative drug companies [7]. - The ETF has surpassed 2 billion yuan in total assets for the first time, with an average daily trading volume of 474 million yuan, making it the largest and most liquid ETF tracking this index [8].
港股通创新药午后走低，再鼎医药重挫10%，520880下探2%跌落10日线，场内溢价飙升！